NASDAQ:ENLV Enlivex Therapeutics (ENLV) Stock Price, News & Analysis $1.27 +0.04 (+3.25%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.22▼$1.2750-Day Range$1.22▼$1.4852-Week Range$1.15▼$4.59Volume4,044 shsAverage Volume106,965 shsMarket Capitalization$26.51 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Enlivex Therapeutics alerts: Email Address Enlivex Therapeutics MarketRank™ Stock AnalysisAnalyst RatingStrong Buy3.50 Rating ScoreUpside/Downside372.4% Upside$6.00 Price TargetShort InterestHealthy0.36% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.81) to ($0.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.75 out of 5 starsMedical Sector382nd out of 910 stocksPharmaceutical Preparations Industry170th out of 426 stocks 3.8 Analyst's Opinion Consensus RatingEnlivex Therapeutics has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageEnlivex Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Enlivex Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.36% of the outstanding shares of Enlivex Therapeutics have been sold short.Short Interest Ratio / Days to CoverEnlivex Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Enlivex Therapeutics has recently decreased by 11.70%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnlivex Therapeutics does not currently pay a dividend.Dividend GrowthEnlivex Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENLV. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for Enlivex Therapeutics this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added Enlivex Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enlivex Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.28% of the stock of Enlivex Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.02% of the stock of Enlivex Therapeutics is held by institutions.Read more about Enlivex Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Enlivex Therapeutics are expected to grow in the coming year, from ($0.81) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enlivex Therapeutics is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enlivex Therapeutics is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnlivex Therapeutics has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Enlivex Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWhy billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. Click here for my exclusive video About Enlivex Therapeutics Stock (NASDAQ:ENLV)Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Read More ENLV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENLV Stock News HeadlinesSeptember 2, 2024 | uk.finance.yahoo.comEnlivex Therapeutics Ltd. (ENLV.TA)August 29, 2024 | americanbankingnews.comEnlivex Therapeutics (NASDAQ:ENLV) Rating Increased to Strong-Buy at EF Hutton Acquisition Co. ISeptember 7, 2024 | Mode Mobile (Ad)Pre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.August 21, 2024 | finance.yahoo.comValneva SE (AYJ0.BE)July 23, 2024 | markets.businessinsider.comEnlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic ArthritisJuly 19, 2024 | finanznachrichten.deEnlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVJune 17, 2024 | globenewswire.comEnlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee OsteoarthritisMay 29, 2024 | globenewswire.comEnlivex Therapeutics Closes up to $15 Million Registered Direct OfferingSeptember 7, 2024 | Mode Mobile (Ad)Pre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.May 28, 2024 | globenewswire.comEnlivex Therapeutics Announces up to $15 Million Registered Direct OfferingMay 21, 2024 | finance.yahoo.comWe're Keeping An Eye On Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn RateApril 29, 2024 | finance.yahoo.comEnlivex CEO Issues Letter to Shareholders – Perspectives on Recent EventsApril 22, 2024 | finance.yahoo.comEnlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee OsteoarthritisApril 18, 2024 | msn.comYet Another Biotech Stock Has Found Success During Tuesday's SessionApril 17, 2024 | msn.comEnlivex Therapeutics (ENLV) Price Target Decreased by 41.67% to 7.14April 16, 2024 | finance.yahoo.comEnlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee OsteoarthritisApril 16, 2024 | globenewswire.comEnlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee OsteoarthritisApril 13, 2024 | stockhouse.comEnlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra(TM) In Patients With SepsisSee More Headlines Receive ENLV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/30/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ENLV CUSIPN/A CIK1596812 Webwww.enlivex.com Phone(728) 662-3301Fax972-2620-8070Employees70Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+372.4%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,070,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-74.23% Return on Assets-61.94% Debt Debt-to-Equity RatioN/A Current Ratio7.86 Quick Ratio7.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.62 per share Price / Book0.78Miscellaneous Outstanding Shares20,872,000Free Float18,309,000Market Cap$26.51 million OptionableOptionable Beta1.03 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Shai Novik M.B.A. (Age 58)Executive Chairman Comp: $528kDr. Oren Hershkovitz Ph.D. (Age 47)Chief Executive Officer Comp: $273.6kMs. Shachar Shlosberger CPA (Age 47)Chief Financial Officer Comp: $126kMr. Veronique Amor-BaroukhSenior Director of OperationsMs. Sigal AradDirector of HRKey CompetitorsOrgenesisNASDAQ:ORGSCervoMedNASDAQ:CRVOElutiaNASDAQ:ELUTMediciNovaNASDAQ:MNOVAnixa BiosciencesNASDAQ:ANIXView All CompetitorsInstitutional OwnershipArmistice Capital LLCBought 1,700,571 shares on 8/15/2024Ownership: 8.148%XTX Topco LtdBought 24,820 shares on 8/12/2024Ownership: 0.119%View All Institutional Transactions ENLV Stock Analysis - Frequently Asked Questions How have ENLV shares performed this year? Enlivex Therapeutics' stock was trading at $2.70 at the beginning of 2024. Since then, ENLV stock has decreased by 53.0% and is now trading at $1.27. View the best growth stocks for 2024 here. How were Enlivex Therapeutics' earnings last quarter? Enlivex Therapeutics Ltd. (NASDAQ:ENLV) released its earnings results on Friday, August, 30th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.06. Who are Enlivex Therapeutics' major shareholders? Enlivex Therapeutics' top institutional shareholders include Armistice Capital LLC (8.15%) and XTX Topco Ltd (0.12%). How do I buy shares of Enlivex Therapeutics? Shares of ENLV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Enlivex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enlivex Therapeutics investors own include VBI Vaccines (VBIV), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Occidental Petroleum (OXY), Pfizer (PFE), Amarin (AMRN) and Fulcrum Therapeutics (FULC). This page (NASDAQ:ENLV) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.